Blog

Leaders from Castor discuss what changes we can expect in clinical research, technology, and data through the lens of three key pillars

Each rare disease research breakthrough offers the promise of a longer, better life for patients who otherwise may…

Tech tools help Digital Therapeutics (DTx) maximize the impact of the real-world data they capture, explore how in this blog from Castor

Digital Therapeutics (DTx) is a rapidly growing space whose players are facing challenges in scaling their businesses, including testing. Learn more about growing successfully.

Cybersecurity has become a concern for Digital Therapeutics (DTx) developers and regulatory bodies. Learn to balance functionality & security.

Researchers are looking to incorporate remote technologies into medical device trials for a wide range of device classifications. This article explores current regulations for various classes of medical devices and how this will impact the need for participants to visit research sites throughout the trial.

A robust digital therapeutics cybersecurity system is integral to protecting users’ sensitive information helps meet regulatory requirements and maintain public trust.

The Castor team is thrilled to see an increasing emphasis on diversity of race, gender, and even geography amongst clinical trial participants. Critically, experts call for not just increased diversity on a statistical basis, but that the studied population is representative of the distribution of the disease.

Although eConsent struggled to gain momentum and wider acceptance pre-pandemic, it’s now a major part of clinical research. In this article, learn three ways eConsent addresses the requirements for valid informed consent.

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.